Display options
Cite
Vuist WM, Van Schaik IN, Van Lint M, et al. The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol. 1997;17(4):301-10doi: 10.1023/a:1027326731945.
Vuist, W. M., Van Schaik, I. N., Van Lint, M., & Brand, A. (1997). The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. Journal of clinical immunology, 17(4), 301-10. https://doi.org/10.1023/a:1027326731945
Vuist, W M, et al. "The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids." Journal of clinical immunology vol. 17,4 (1997): 301-10. doi: https://doi.org/10.1023/a:1027326731945
Vuist WM, Van Schaik IN, Van Lint M, Brand A. The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol. 1997 Jul;17(4):301-10. doi: 10.1023/a:1027326731945. PMID: 9258769.
Copy Download .nbib Format: NLM
Share it on

J Clin Immunol. 1997 Jul;17(4):301-10. doi: 10.1023/a:1027326731945.

The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Journal of clinical immunology

W M Vuist, I N Van Schaik, M Van Lint, A Brand

Affiliations

  1. Department of Immunohematology and Bloodbank, Academical Hospital Leiden, The Netherlands.

PMID: 9258769 DOI: 10.1023/a:1027326731945

Abstract

Intravenous human IgG (IVIg) given to patients with autoimmune disorders can result in significant clinical improvement in some patients. The mechanism(s) by which IVIg induces these improvements is(are) not known. We have previously shown that IVIg inhibited the proliferation of peripheral blood lymphocytes in allogeneic mixed lymphocyte reactions and of autonomously growing human and mouse cell lines. In an effort to identify the antigen(s) to which the human IgG binds, the human B cell line JY, whose proliferation was inhibited by IVIg, was incubated with IVIg, washed extensively with PBS, and lysed. Human IgG from these lysates was purified by protein A-Sepharose (IVIgJY). IVIgJY binds to and inhibits the proliferation of JY cells and of peripheral blood lymphocytes stimulated in a MLR at a 1000- to 10,000-fold lower concentration compared to IVIg. IVIgJY was analyzed on a 5-15% gradient SDS/PAGE and only immunoglobulin heavy- and light-chain (run under reducing conditions) proteins were detected. Immunoprecipitation experiments from JY cell lysates with IVIgJY indicated that this IgG did not bind to a protein epitope. Thin-layer immunoblot experiments showed that the IVIgJY binds to glycolipids expressed by JY cells and lymphocytes. Furthermore, evidence is presented indicating that antiglycolipid antibodies are involved in IVIg-induced growth inhibition.

References

  1. Br J Haematol. 1988 Aug;69(4):507-11 - PubMed
  2. Immunopharmacol Immunotoxicol. 1990;12(4):545-63 - PubMed
  3. N Engl J Med. 1982 May 27;306(21):1254-8 - PubMed
  4. Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S82-6 - PubMed
  5. Br J Haematol. 1985 Jun;60(2):315-22 - PubMed
  6. J Clin Invest. 1987 Feb;79(2):468-72 - PubMed
  7. J Rheumatol. 1991 Jun;18(6):937-9 - PubMed
  8. N Engl J Med. 1991 Jul 11;325(2):110-7 - PubMed
  9. J Pediatr. 1986 Jan;108(1):77-81 - PubMed
  10. J Immunol. 1981 Aug;127(2):572-5 - PubMed
  11. Proc Natl Acad Sci U S A. 1987 Feb;84(3):828-31 - PubMed
  12. Lancet. 1991 May 11;337(8750):1137-9 - PubMed
  13. Clin Immunol Immunopathol. 1994 Nov;73(2):180-6 - PubMed
  14. Ann Intern Med. 1990 Feb 15;112(4):278-92 - PubMed
  15. N Engl J Med. 1987 Oct 15;317(16):1004-8 - PubMed
  16. J Immunol. 1991 Sep 1;147(5):1530-6 - PubMed
  17. Immunology. 1991 Apr;72(4):497-501 - PubMed
  18. J Clin Invest. 1989 Dec;84(6):1974-81 - PubMed
  19. Am J Med. 1991 Nov 4;91(5A):35S-39S - PubMed
  20. Br J Haematol. 1995 Apr;89(4):698-703 - PubMed
  21. J Clin Immunol. 1992 Sep;12(5):325-34 - PubMed
  22. J Immunol. 1986 Oct 1;137(7):2100-6 - PubMed
  23. Transfusion. 1992 May;32(4):361-76 - PubMed
  24. N Engl J Med. 1992 Jan 9;326(2):107-16 - PubMed
  25. Immunology. 1993 Jun;79(2):211-6 - PubMed
  26. J Clin Immunol. 1995 Jul;15(4):172-8 - PubMed
  27. Br J Haematol. 1990 Dec;76(4):513-20 - PubMed
  28. Immunopharmacol Immunotoxicol. 1990;12(4):565-82 - PubMed
  29. Biochim Biophys Acta. 1980 Jan 18;617(1):97-109 - PubMed
  30. Immunol Rev. 1989 Aug;110:105-17 - PubMed
  31. Scand J Immunol. 1993 Nov;38(5):477-84 - PubMed
  32. J Immunol. 1986 Jun 15;136(12):4407-13 - PubMed
  33. Clin Exp Immunol. 1986 Aug;65(2):409-15 - PubMed
  34. Adv Intern Med. 1987;32:111-35 - PubMed
  35. Transplantation. 1982 Feb;33(2):118-22 - PubMed
  36. J Clin Immunol. 1991 May;11(3):152-8 - PubMed
  37. Clin Exp Immunol. 1991 Nov;86(2):192-8 - PubMed
  38. Springer Semin Immunopathol. 1995;17(1):29-42 - PubMed
  39. J Immunol. 1987 Oct 1;139(7):2123-9 - PubMed

Substances

MeSH terms

Publication Types